Semler Scientific under investigation by Faruqi & Faruqi for securities fraud.
PorAinvest
miércoles, 8 de octubre de 2025, 10:06 am ET1 min de lectura
SMLR--
The complaint alleges that Semler Scientific discussed potential violations of the False Claims Act in hypothetical terms without disclosing an ongoing DOJ investigation. The company's public statements were found to be false and materially misleading during the class period. The lawsuit claims that investors suffered damages as a result of these misrepresentations [2].
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific. The firm encourages investors who suffered losses to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
The deadline to seek the role of lead plaintiff in the federal securities class action is October 28, 2025 [2]. Investors who purchased shares during the specified period are encouraged to contact the firm to discuss their participation in the lawsuit.
Faruqi & Faruqi LLP is investigating potential claims against Semler Scientific, a biotechnology company. The investigation focuses on potential securities law violations between March 10, 2021, and April 15, 2025. Investors who suffered losses in Semler Scientific are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek the role of lead plaintiff is October 28, 2025.
Semler Scientific, Inc. (NASDAQ: SMLR), a biotechnology company, is facing a class action lawsuit alleging securities law violations. The lawsuit, filed on behalf of investors who purchased shares during the period from March 10, 2021, to April 15, 2025, accuses the company of making false and misleading statements and failing to disclose a material investigation by the U.S. Department of Justice (DOJ) into violations of the False Claims Act [2].The complaint alleges that Semler Scientific discussed potential violations of the False Claims Act in hypothetical terms without disclosing an ongoing DOJ investigation. The company's public statements were found to be false and materially misleading during the class period. The lawsuit claims that investors suffered damages as a result of these misrepresentations [2].
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific. The firm encourages investors who suffered losses to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
The deadline to seek the role of lead plaintiff in the federal securities class action is October 28, 2025 [2]. Investors who purchased shares during the specified period are encouraged to contact the firm to discuss their participation in the lawsuit.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios